Generics & Biosimilars | Association for Accessible Medicines
New Blog - Jonathan Kimball gives more detail re: AAM's blueprint & proposed policy framework
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
  • Generics and Biosimilars Supply Chain Presentation COVID-19
    New Resource Available
    Generics and Biosimilars Industry Response to COVID-19 Presentation. Schematic and explanation of generic supply chain. Plus, how AAM members are rising to the challenge of COVID-19:
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
  • COVID-19 Response - Patient Access to Medicines
    COVID-19: Ensuring Americans Have Access to Their Medicines
    America’s generic and biosimilar manufacturers are committed to meeting the health care needs of patients in the U.S.

Recent Updates

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.